REVIEW ARTICLE

A critical role of the thioredoxin domain containing protein 5 (TXNDC5) in redox homeostasis and cancer development

Hedy A. Chawsheen a, Qi Ying a, Hong Jiang a, Qiou Wei a,b,*

a Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, KY 40536, USA
b Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA

Received 16 July 2018; accepted 25 September 2018
Available online 28 September 2018

Abstract Correct folding of nascent peptides occurs in the endoplasmic reticulum (ER). It is a complex process primarily accomplished by the coordination of multiple redox proteins including members of the protein disulfide isomerase (PDI) family. As a critical member of the PDI family, thioredoxin domain containing protein 5 (TXNDC5) assists the folding of newly synthesized peptides to their mature form through series of disulfide bond exchange reactions. Interestingly, TXNDC5 is frequently found overexpressed in specimens of many human diseases including various types of cancer. In this review, we summarized the biochemical function of TXNDC5 in mammalian cells and the recent progress on the understanding of its role and molecular mechanisms in cancer development. Findings of TXNDC5 in the activation of intracellular signaling pathways, stimulation of cell growth & proliferation, facilitation of cell survival and modulation of extracellular matrix to affect cancer cell invasion and metastasis are reviewed. These published studies suggest that strategies of targeting TXNDC5 can be developed as potentially valuable methods for the treatment of certain types of cancer in patients.

* Corresponding author. Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, KY 40536, USA. Fax: +1 859 323 1059.
E-mail address: qiou.wei@uky.edu (Q. Wei).

Peer review under responsibility of Chongqing Medical University.

https://doi.org/10.1016/j.gendis.2018.09.003
2352-3042/2018, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Redox imbalance is one of the major contributing factors of many types of human diseases, including cancer. Mechanisms of redox communication and cellular response to the waves of reactive oxygen species under various conditions are yet to be completely understood. Oxygen and hydrogen peroxide are two examples of diametric molecules that can function as pro- as well as anti-survival elements, through either enhancing growth signaling or causing destructive effect on nucleotides, lipids, and proteins. In this process, there are numerous redox enzymes that not only shelter cellular components from oxidative damages, but also recycle damaged molecules through disulfide exchange reactions to maintain redox homeostasis. Among these is the superfamily of thioredoxin, which includes thioredoxin, peroxiredoxin (Prx), ferroredoxin, glutaredoxin, quiescin sulf hydryl oxidase, vitamin K, epoxide reductase, PDI, etc. Most of these enzymes share a common structural characteristic of containing thioredoxin or thioredoxin-like domains, through which thiol-disulfide exchange reactions are fulfilled. TXNDC5 is a particular member of the family of PDI. In this review, we summarized the findings of most recent studies on the understanding of the role and molecular mechanisms of TXNDC5 in human diseases including cancer development.

Orthologs of TXNDC5 are present in many eukaryotic organisms including yeast, lancelet, drosophila, zebra fish, lizards, mouse, elephant, and chimpanzee. In human, TXNDC5 gene, alias ERp46, PDIA15, HCC-2, or EndoPDI, is located in chromosome 6p24.3. It encodes five splicing introns and two protons must be transferred to the disulfide bond with the oxidative state of $1/C_0$.

Generation of disulfide bond in TXNDC5

Proper folding of newly synthesized plasma membrane and secretory proteins is one of the major functions of the ER in healthy cells. Protein folding occurs when the electron transport takes place between an electron acceptor protein (oxidant) and electron donor protein (reductant). Appropriate formation/breakdown of disulfide bond is one of the critical pathways to ensure the flow of electrons between oxidant and reductant proteins in the cell. These reactions eventually guarantee the synthesis of physiologically functional proteins. In addition to their chaperone activity, members of the PDI family actively participate in the oxidation, reduction, and isomerization of nascent peptides in the ER. To function on a newly synthesized peptide, the PDI needs to be in an oxidized state, which is established through a redox sensitive thiol group in its primary sequence by a number of oxidoreductase and oxygen derived molecules. Each of the sulfur in the thioredoxin-like domain of the PDI is in an oxidative state of $-2$. Therefore, to form a disulfide bond with the oxidative state of $-1$, two electrons and two protons must be transferred to the oxidant. Once the sulfur containing cysteine residues are in close vicinity, thermodynamically favored reaction will be established through molecular oxygen. However, the reaction is slow and requires other enzymes to catalyze the disulfide bond formation within the PDI. There are several well-established pathways involved in generating disulfide bonds in mammalian PDIs through thiol-disulfide exchange reactions. Enzymes required for these pathways including flavoenzyme, ER oxidoeductin 1 (Ero1), Prx, vitamin K epoxide reductase, glutathione peroxidase 7 and 8, as well as reductase for the reduction of dehydroascorbate to ascorbate.

Among these, TXNDC5 is found to interact with Ero1 and Prxs, particularly Prx2 and Prx4. It is worth to note that the nascent protein can also be folded into the native form through the involvement of other enzymes such as the quiescin sulf hydryl oxidase pathway, which is independent of the PDI members.
When the ER is shifting toward a reducing environment, it stimulates flavin adenine dinucleotide bound to Ero1. The latter acts on molecular oxygen to generate hydrogen peroxide, leading to the oxidation of the PDI family members including TXNDC5. The thioredoxin-like domains of TXNDC5 enable its enzymatic function including the oxidase and reductase activity, which is essential for the disulfide exchange reaction occurred in the physiologic environment of mammalian cells. Interestingly, three thioredoxin-like domains of TXNDC5 work independently from each other to accelerate the process of protein folding. In contrast, similar domains of other PDIs work cooperatively and resulting in much slower rate of substrate folding. With an extended long loop, the C-terminal thioredoxin-like domain of TXNDC5 acquires a unique V-shape configuration, which distinguishes it from the U-shaped feature of other PDI members, such as ER protein 57 and protein 72. This unique feature enables TXNDC5 an essential role in disulfide bond exchange and nascent peptide folding.

2-cys containing Prxs, particularly the homodecamer that is composed of five pairs of 2-cys Prx4, are also involved in the oxidation of the PDIs. For this reaction, the affinity of 2-cys Prxs to TXNDC5 is much higher than to the other PDI members. In Jurkat and human umbilical vein endothelial cells, the C-terminal thioredoxin-like domain of TXNDC5 is found to selectively interact with the resolving cysteine of Prx2. This interaction is present in plasma membrane and cytosol. Therefore, TXNDC5 transmits the redox signal from hydrogen peroxide sensors to the substrate through series of disulfide bond formation involving the reduction of Ero1 and dimeric forms of Prx2 or Prx4.

When TXNDC5 passes the disulfide bond to the substrate, its disulfide bond is reduced. In addition to the nascent peptides, glutathione is also known to be capable of reducing the thioredoxin domain of PDI at pH 7.4 in vitro. Furthermore, some members of the PDI family also have the reductase activity. For example, the reductase activity of ERdj5 is involved in the reduction of misfolded proteins in the ER. This function of ERdj5 is important for the degradation of misfolded proteins occurred outside of the...
ER, as well as the correction of misfolded proteins to their native forms within. In this context, the reductase activity of these PDIs is comparable to the thioredoxin reductase, which employs NAD(P)H to reduce the oxidized cysteine in thioredoxin domain. Therefore, it is possible that the disulfide bond of TXNDC5 is reduced through its interaction with glutathione or ERdj5 in the ER. However, there is a lack of experimental evidence to elaborate the exact mechanism by which oxidized TXNDC5 is reduced in cells.

Mechanism of TXNDC5-substrate/thiol-disulfide exchange in cells

The redox status of different cellular compartments is not even, with the general conception of being reducing and hypoxic in the cytosol, oxidizing and normoxic in the extracellular cell milieu, and oxidizing in the ER. Potential disulfide bond exchange between TXNDC5 and its substrate is determined by the redox status of local environment. In general, members of the PDI family take part in the processes of reduction, oxidation, and isomerization of disulfide bonds to facilitate the maturation of nascent peptides to native proteins in the ER (Fig. 3).

Figure 2  Possible substrates of oxidative folding in endothelial reticulum carried out by TXNDC5. (A) The thioredoxin domain of Vitamin K epoxide reductase (VKOR) is oxidized during the reduction process of vitamin K epoxide to vitamin K. The disulfide bond of VKOR is reduced by TXNDC5. (B) Hydrogen peroxide (H₂O₂) oxidizes glutathione peroxidase 7 and 8 (GPx7, 8) and the disulfide bond is exchanged to TXNDC5. (C) Ero1 used molecular oxygen to generate disulfide bond and releasing H₂O₂ then passes the disulfide bond to TXNDC5. (D) Dehydroascorbate is reduced to ascorbate by TXNDC5. (E) The disulfide bond in Prx4 is reduced by TXNDC5. (F) Quiescin-sulfhydryl oxidase (QSOX) couples the generation of disulfide bonds to the reduction of molecular oxygen, and the disulfide is passed directly to other substrates. Disulfide bond generated through the coupling of TXNDC5 with Ero1 or Prx4 has been experimentally validated (depicted in the dashed box).
the sulfur atom of the disulfide bond, through which the thiol-disulfide exchange occurs. Glutathione and glutathione reductase are among the proteins that contribute to the thiol activation of PDI. The pH of normal ER is about 7.2, while the extracellular pH is about 7.4. Therefore, under physiological conditions, the pKa of the N-terminal thiol is about 4.5–6.7. PDI with active $S^-/C_0^+$ can also break the bond in the form of other oxidative modifications, such as the bond between nitric oxide and sulfur in S-nitrosothiol. As to TXNDC5, the oxidation of the nascent peptide takes place when the $S^-/C_0^+$ ion exerts a nucleophile attack on the sulphydryl group of the substrate, resulting in a mixed disulfide bond. The latter is resolved when the second cysteine of the thioredoxin-like domain attacks, leading to the release of the substrate from TXNDC5. Thus the substrate is left with an active $S^-$ ion, which will then attack and deprotonate a nearby sulphydryl group to form a disulfide bond.

The formation of appropriate disulfide bond will stabilize the structure of protein and thus increase its halflife. For instance, the formation of disulfide bond between Cys68-Cys98 of subtilisin E increases its half-life for nearly three folds. Such effect of stabilization is resulted from the increase of the melting temperature. Moreover, the formation of disulfide bond can also affect the protein activity, either positively or negatively depending on the location of the disulfide bond. On the other hand, formation of non-native disulfide bonding may create intermediates leading to protein aggregation and precipitation. Such effect will potentially produce undesirable consequences in cells, and should be avoided in the design of proteins aimed for therapeutic purpose.

**Other possible modifications of TXNDC5**

Besides disulfide bond formation, protein thiols are also subjected to other redox related modifications. For example, protein thiols undergo S-nitrosylation in response to nitrosative stress. S-thiolation of TXNDC5 leads to the formation of disulfide bond with cysteine, homocysteine, cysteinylglycine and glutathione, and such modifications share the characteristic of having low molecular weight. S-nitrosylation can be potentially harmful since increased levels of S-nitrosylation in PDIs have been reported in human disorders such as Parkinson’s and Alzheimer’s diseases. Moreover, thiols can also be oxidized by reactive oxygen species to produce sulfenic form (SOH) with an oxidation state of zero, or overoxidized to form sulfonic form (SO$_2$H) with an oxidation state of +2, and even sulfonic acid (SO$_3$H) with an oxidation state of +4. The oxidized thiol plays a role in cell signaling and is an important intermediate in disulfide bond formation. The overoxidized thiols are intermediates of cysteine metabolism and can function as agonists for certain receptors. In general, the overoxidation of protein thiols are considered irreversible. However, the overoxidation of thiols in Prxs can be reduced back to their oxidized form through the reducing activity of sulfiredoxin. Theoretically, thiols in the thioredoxin folds of TXNDC5 are also likely undergo above mentioned modifications. Currently, there are no sufficient studies involving the thiol modification of TXNDC5. Therefore, the significance of such modifications in TXNDC-5 mediated cell signaling is still not clear.

**TXNDC5 and cancer**

**TXNDC5 is highly expressed in human cancer**

As evidenced from results of immunohistochemical staining and western blotting of patient specimens, abnormally high expression of TXNDC5 protein has been found in many types of human tumors, including cancers of lung, prostate, colon, breast, esophagus, liver, gastro and ovary. In lung cancer, more than sixty percent of non-small cell lung cancer specimens has elevated TXNDC5 expression compared with adjacent normal tissue. Such increase of TXNDC5 expression is found at both transcriptional and
translational levels, in particular, in the early stage of tumor formation. Similar findings were reported in colon cancer, in which nearly eighty percent of specimens has increased level of TXNDC5; and significant higher level is found in the early stage of cancer development. Another study using specimens from colorectal cancer patients also reveals the upregulation of TXNDC5 in the early stage of colon cancer. Nissam and his group reported that TXNDC5 is upregulated in poorly differentiated hepatocellular carcinoma. In human gastric adenocarcinoma, TXNDC5 is elevated in most of the examined samples and significantly high level of TXNDC5 is observed especially in poorly differentiated cancer. In prostate tumors, TXNDC5 is upregulated in androgen naïve prostate cancer and castration-resistant prostate cancer. Taken together, these studies suggest that TXNDC5 is highly expressed in different types of human tumors and may play a potential role in cancer development.

Mechanisms of TXNDC5 to promote cancer development

TXNDC5 affects tumor cells’ response to extracellular oncogenic signaling through interacting with receptors on the plasma membrane. The majority of TXNDC5 protein is localized in the ER and Golgi, where it plays a critical role in protein folding and anterograde transport. However, nearly one fifth of TXNDC5 is present in plasma membrane, where it is presumably involved in the transduction of extracellular signaling events. Other membrane localized PDI s, such as PDA16, were reported to be involved in signal activation and remodeling through binding to receptors in the plasma membrane. For example, PD13 binds and participates in the activation of z1ß1 fibrinogen and ß3 subunit and participates in platelet aggregation. It is thus reasonable to believe that TXNDC5 also plays such a role in the transduction of certain membrane receptor signaling. Indeed, TXNDC5 is found to interact with few membrane receptors such as adiponectin receptor. Specifically, TXNDC5 interacts with the N-terminal domain of AdipoR1 and this interaction is critical for receptor remodeling. In HeLa cells, increased distribution of TXNDC5 on plasma membrane inhibits adiponectin signaling through reducing the distribution of AdipoR1 on the cell surface. In renal cell carcinoma, there is a high ratio of TXNDC5/AdipoR1 in metastatic RCC compared to non-metastatic control; and the presence of TXNDC5 in metastatic RCC promotes cell invasion, enhances tumor xenograft growth in nude mice. Another example of TXNDC5 in membrane receptor signaling is the activation of androgen receptor (AR). In prostate cancer, TXNDC5 is found to directly interact with AR. The TXNDC5-AR interaction stabilizes AR and protects it from degradation, thus more AR can be translocated into the nucleus upon ligand binding, leading to an enhanced activation of downstream signaling. In particular, this mechanism functions as an alternative pathway to enhance AR activation in castration-resistant prostate cancer when the amount of androgen is limited. By stabilizing AR and increasing the sensitivity of cells to androgen, TXNDC5 promotes abnormal activation of epidermal growth factor receptor 2, leading to the sustained activation of protein kinase B and extracellular signal-regulated kinase cascades even when there’s limited ligand presence. Moreover, TXNDC5 is also reported to affect mitogen activated protein kinase (MAPK) signaling through the TNFα-TNF receptor activation, and this effect exists upstream of c-Raf in the MAPK cascade. Therefore, it is conceivable that TXNDC5 may interact directly with tumor necrosis factor (TNF) receptor. However, further studies are needed to test this interaction and determine how this interaction affects the TNFα-mediated cell signaling.

Expression of TXNDC5 increases tumor cell proliferation. A close examination of TXNDC5 on cell cycle progression reveals that its expression increases the number and percentage of cells in G2/M phase, whereas knockdown of TXNDC5 leads to the accumulation of cells in G0/G1 phase. In gastric cancer cells, elevated level of TXNDC5 contributes to increased rate of cell proliferation, migration, colony formation and reduced rate of apoptosis. The anti-apoptotic function of TXNDC5 is also supported by findings from pancreatic cancer, where the orphan nuclear receptor 4A1 (NR4A1) and TXNDC5 are overexpressed. In these cells, activation of NR4A1 protects cells from damages caused by ER stress. Such effect of NR4A1 is closed associated with the transcriptional activation of TXNDC5. Down-regulation of TXNDC5 results in the defragmentation of ER and altered expression of many ER proteins, such as ATF-4, GRP78, IDH1, TXNDC5 and CCAAT/enhancer-binding protein homologous protein. Therefore, the protective effect of NR4A1 is mediated at least partially through the expression of TXNDC5, which reduces ER stress and facilitates cell survival. Moreover, TXNDC5 contributes to tumor cell survival and growth under hypoxia environment. In addition to cancer cells, TXNDC5 is also found to be highly expressed in endothelial tissue of tumors and atherosclerotic plaques, particularly under hypoxic condition. Knockdown of TXNDC5 leads to the reduced expression of endothelin-1, adrenomedullin and CD105. These molecules are known to facilitate the survival of endothelial cells. Through enhancing the expression of these molecules, TXNDC5 may protect cancer cells from hypoxia induced cell death. Treatment of prostate cancer by androgen deprivation often leads to an increased expression of TXNDC5, which is mediated through hypoxia-induced activation of HIF-1α and miR-200b pathways. The hypoxic condition fortifies the interaction between TXNDC5 and AR and conceivably further enhances downstream signaling including the activation of ERK1/2, AKT and MEK pathways. Mechanistically, TXNDC5 is negatively regulated by miR-200b since it binds and targets the 3’ UTR of TXNDC5 mRNA for degradation. However, miR-200b is also negatively regulated by HIF-1α. Under hypoxia condition, the degradation of HIF1α is reduced, leading to its stabilization, accumulation and translocation to nuclear. Therefore, the inhibition of miR-200b by HIF1α leads to the increase of TXNDC5 under hypoxia, which is positively associated with increased cell migration and invasion.

Furthermore, the presence of TXNDC5 leads to the change of extracellular microenvironment that facilitates cancer cell invasion and metastasis. In gastric
adenocarcinoma, expression of TXNDC5 promotes cancer cell invasion and metastasis. TXNDC5 is highly expressed in gastric cancer compared with normal surrounding tissue. Knockdown of TXNDC5 in gastric adenocarcinoma MKN45 cells significantly reduces their malignancy. In prostate cancer, TXNDC5 is upregulated in androgen naïve prostate cancer and castration-resistant prostate cancer. Silencing of TXNDC5 in androgen-independent prostate cancer cells inhibits cell invasion, and overexpression of TXNDC5 stimulates tumor xenograft growth in nude mice. Similar observation is also found in HeLa cells, since knockdown of TXNDC5 leads to the reduced activation of p38 mitogen-activated protein kinases. In human umbilical vein endothelial cells, knockdown of TXNDC5 leads to reduced activation of Ras/Raf and downstream ERK1/2 in response to inflammatory cytokines such as TNFα. The insufficient activation of ERK1/2 results in a decreased activity of activator protein-1 (AP-1). Among the downstream target genes of AP-1 regulation, there are various protein proteases including matrix metalloproteinase (MMP) 9 and cathepsin B. Down-regulation of these protease has a negative effect on the angiogenesis of endothelial cells. Moreover, TXNDC5 also promotes the expression of MMP1 and MMP13, which play significant role in cancer cell invasion and metastasis. In particular, MMP13 has been associated with tumor angiogenesis through promoting the secretion of VEGF in endothelial cells and fibroblasts. Through the upregulation of matrix metalloproteinase, TXNDC5 enhances cancer cell invasion and metastasis. Based on these findings, we summarized the possible mechanistic contributions of TXNDC5 in human cancer development (Fig. 4).

**TXNDC5 in other diseases**

In addition to cancer, TXNDC5 also plays important role in other types of human disease. In patients with rheumatoid arthritis, the levels of TXNDC5 in plasma and synovial fluid are significantly higher compared with normal control. Epidemiological studies reveals that a single nucleotide polymorphism rs443861 is associated with an increased risk of rheumatoid arthritis. The increased level of TXNDC5 in rheumatoid arthritis is not resulted from the autoimmune response, but rather is the response to hypoxia. Moreover, TXNDC5 is believed to have a pro-inflammatory function that contributes to synovial membrane angiogenesis, aberrant cell differentiation and bone destruction in rheumatoid arthritis. Mechanistically, adiponectin is found to be significantly increased in the synovial site. TXNDC5 can modulate adiponectin signaling since it directly interacts with adiponectin receptor. Furthermore, the expression of multiple factors including MMP1, MMP13, VEGF, IL-6, IL-8 and other cytokines is enhanced by TXNDC5-mediated intracellular signaling. Among these, MMP1 and MMP13 facilitate the degradation of collagenous extracellular matrix; and cytokines stimulate further inflammatory cell infiltration and synovial cell death. At the later stage of rheumatoid arthritis, TXNDC5 also contributes to the deterioration of osteoblast and bone destruction.

Genetic polymorphism of TXNDC5 gene is also associated with other types of diseases in humans. For example, certain SNPs of TXNDC5 are positively linked to non-segmental vitiligo, a condition featured by the loss of melanocyte in the skin. In Korean males, a case-control study of 230 subjects reveal that rs1043784, rs7764128 and rs8643, located on TXNDC5 exons, are significantly associated with NSV. As a result of autoimmune response or oxidative stress, these SNPs can negatively affect the anti-apoptotic activity of TXNDC5, leading to the progressive loss of melanocytes. Moreover, TXNDC5 SNPs are found to be associated with increased vulnerability to schizophrenia. In families with at least two siblings suffered from schizophrenia, genetic analyses found that the locus 6p24.3 is linked to cognitive impairment. In particular, SNP rs13873 of TXNDC5 gene and the haplotype rs1225934-rs13873 of the BMP6-TXNDC5 genes on chromosome six are associated with a high risk of schizophrenia.

Increased expression of TXNDC5 may also contribute to the progression of diabetes. In patients with autoimmune antibodies that attack insulin producing β-cells, the level of TXNDC5 is increased and positively associated with a higher risk of type 1 diabetes. In type II diabetes, TXNDC5 is identified as one of the important response components of glucose toxicity. Interestingly, pancreatic cells’ response to high glucose exposure may include a reduced expression of TXNDC5 but increased expression of other PDI family members. For instance, in a study of hepatic insulin resistance in hamster, the level of TXNDC5 is found to be reduced by nearly two folds, whereas expression of other PDIs increases in fructose-fed insulin-resistant animals. Therefore, these studies reveal that there is a possible association between TXNDC5 and hepatic insulin signaling. However, the mechanism by which TXNDC5 affects insulin signaling has yet to be determined.

**Other PDIs in cancer**

The human PDI family can be divided into three subgroups and some unusual subfamilies. The first group includes five typical PDIs (PDIA 1–5) and PDILT, each containing two catalytically active a-type domains (a and a’ domains) and two inactive b-type domains (b and b’ domains). Proteins in the second group contain only enzymatically active thioredoxin-like domains including ERP44, TXNDC5, PDIA6 and DNAJC10. The third group comprises TXM 1–4, which carrying only one a-type domain are the only PDI proteins with a transmembrane domain. Erp27, Erp29, TXNDC12, AGR2 and AGR3 can be considered as unusual members of the PDI family. These proteins contain single a-type domain thus have lower molecular weight (<30 kDa), except for Erp27, which has two b-type domains. CASQ1 and CASQ2 belong to another unique subfamily, which has only b-type domains and no ER-retention sequence. Although functions of PDI proteins in cancer progression are complex, many published researches suggested that these proteins are frequently up-regulated in various cancers. Analyses of proteomes and microarray data indicated that PDIA1, PDIA3, PDIA4 and PDIA6 are highly expressed in brain, liver, breast, prostate and...
Figure 4  Mechanisms of TXNDC5 in cell signaling and cancer development. Binding of ligands to membrane receptors, such as AdipoR1 and tyrosine kinase receptors, stimulates signaling cascades that activate transcription factors including AP-1 and NR4A1. TXNDC5 is a downstream target of such activation. In addition, binding of miR-200R to the 3'-UTR of TXNDC5 transcripts leads to the degradation of mRNA and low expression under normoxia conditions. Hypoxia leads to the downregulation of miR-200b, which results in the upregulation of TXNDC5. Increased level of TXNDC5 can further enhance membrane receptor signaling through direct interaction or receptor stabilization. The presence of TXNDC5 facilitates the folding of nascent peptides and reduces ER stress through its chaperone activity, and this process may also involve the contribution from other enzymes, such as Prx4 and Ero1. Collectively, TXNDC5 enhances cell growth and proliferation, ER homeostasis and angiogenesis to promote cancer development.

Role of the thioredoxin domain containing protein 5 (TXNDC5)
function that can promote the development of cancer and other types of diseases in humans. Therefore, it can be considered as an important target for the development of cancer therapeutics. In addition to TXNDC5, increased levels of other PDIs are also found in different types of cancer. Expression of these PDIs may contribute to cancer cell proliferation, invasion and metastasis. Currently there are no therapeutic drugs that have been approved to specifically target TXNDC5 or other PDIs for the treatment of cancer in patients.

Conflict of interests

There is no conflict of interests.

Acknowledgment

This work was partially supported by the National Institutes of Health (NCI grant number RO1CA222596), Department of Defense (grant number W81XWH-16-1-0203), American Cancer Society (grant number RSG-16-213-01-TBE) and Kentucky Lung Cancer Research Program (KLCRP2016). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding agencies.

We would like to thank Library of Science and Medical Illustrations and Servier Medical Art for sharing their biological illustrated shapes online that was used to create the figures of this review article. We also appreciate the assistance of Mr. Zana Rafiq Majeed in the preparation of this manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gendis.2018.09.003.

References

1. Xu S, Sankar S, Neamatli N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today. 2014; 19(3):222–240.
2. Horna-Terron E, Pradilla-Dieste A, Sanchez-de-Diego C, Osada J. TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology. Int J Mol Sci. 2014; 15(12):23501–23518.
3. Prakash T, Sharma VK, Adati H, et al. Expression of conjoined genes: another mechanism for gene regulation in eukaryotes. PLoS One. 2010;5(10), e13284.
4. Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat Struct Mol Biol. 2009;16(2):107–113.
5. Benham AM. The protein disulfide isomerase family: key players in health and disease. Antioxid Redox Signal. 2012; 16(8):781–789.
6. Sullivan DC, Huminiecki L, Moore JW, et al. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem. 2003;278(47):47079–47088.
7. Funkner A, Parther C, Schutkowski M, et al. Peptide binding by catalytic domains of the protein disulfide isomerase-related protein ERp46. J Mol Biol. 2013;425(8):1340–1362.
8. Nissom PM, Lo SL, Lo JC, et al. Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma. FEBS Lett. 2006;580(9):2216–2226.
9. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725–738.
10. Bulleid NJ. Disulfide bond formation in the mammalian endoplasmic reticulum. Cold Spring Harb Perspect Biol. 2012;4(11).
11. Hatafet F, Ruddock LW. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. Antioxid Redox Signal. 2009;11(11):2807–2850.
12. Rutkевич LA, Williams DB. Vitamin K epoxide reductase contributes to protein disulfide formation and redox homeostasis within the endoplasmic reticulum. Mol Biol Cell. 2012;23(11):2017–2027.
13. Wang L, Zhang L, Niu Y, Sitia R, Wang CC. Glutathione peroxidase 7 utilizes hydrogen peroxide generated by Ero1alpha to promote oxidative protein folding. Antioxid Redox Signal. 2014;20(4):545–556.
14. Saaranen MJ, Karala AR, Lappi AK, Ruddock LW. The role of dehydroascorbate in disulfide bond formation. Antioxid Redox Signal. 2010;12(1):15–25.
15. Sato Y, Kojima R, Okumura M, et al. Synergistic cooperation of PDI family members in peroxiredoxin 4-driven oxidative protein folding. Sci Rep. 2013;3:2456.
16. Pace PE, Peskin AV, Han MH, Hampton MB, Winterbourn CC. Hyperoxidized peroxiredoxin 2 interacts with the protein disulfide-isomerase ERp46. Biochem J. 2013;453(3):475–485.
17. Bulleid NJ, Ellgaard L. Multiple ways to make disulfides. Trends Biochem Sci. 2011;36(9):485–492.
18. Kojima R, Okumura M, Masui S, et al. Radically different thioredoxin domain arrangement of ERp46, an efficient disulfide bond introducer of the mammalian PDI family. Structure. 2014; 22(3):431–443.
19. Oka OB, Pringle MA, Schopp IM, Braakman I, Bulleid NJ. ERdj5 is the ER reductase that catalyzes the removal of non-native disulfides and correct folding of the LDL receptor. Mol Cell. 2013;50(6):793–804.
20. Jordan PA, Stevens JM, Hubbard GP, et al. A role for the thioloredoxin protein ERp5 in platelet function. Blood. 2005; 105(4):1500–1507.
21. Essex DW. Redox control of platelet function. Antioxid Redox Signal. 2009;11(5):1191–1225.
22. Trivedi MV, Laurence JS, Siahaan TJ. The role of thiols and disulfides on protein stability. Curr Protein Pept Sci. 2009; 10(6):614–625.
23. Takagi H, Takahashi T, Momose H, et al. Enhancement of the thermostability of subtilisin E by introduction of a disulfide bond engineered on the basis of structural comparison with a thermostophilic serine protease. J Biol Chem. 1999;265(12):6874–6878.
24. Nakamura T, Tu S, Akhtar MW, Sunico CR, Okamoto S, Lipton SA. aberrant protein S-nitrosylation in neurodegenerative diseases. Neuron. 2013;78(4):596–614.
25. Nakamura T, Prikhodko OA, Pirie E, et al. aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol Dis. 2015;84:99–108.
26. Biteau B, Labarre J, Toledano MB. ATP-dependent reduction of cysteine-sulphenic acid by S. cerevisiae sulphiredoxin. Nature. 2003;425(6961):984.
27. Chang TS, Jeong W, Woo HA, Lee SM, Park S, Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfenic acid in the active site to cysteine. J Biol Chem. 2004; 279(49):50994–51001.
28. Chang X, Xu B, Wang L, Wang Y, Yan S. Investigating a pathogenic role for TXNDC5 in tumors. Int J Oncol. 2013;43(6): 1871–1884.
29. Vincent EE, Elder DJ, Phillips L, et al. Overexpression of the TXNDC5 protein in non-small cell lung carcinoma. *Anticancer Res.* 2011;31(5):1577–1582.

30. Tan F, Zhu H, He X, et al. Role of TXNDC5 in tumorigenesis of colorectal cancer cells: in vivo and in vitro evidence. *Int J Mol Med.* 2018;42(2):935–945.

31. Wang Y, Ma Y, Lu B, Xu E, Huang Q, Lai M. Differential expression of mimicam and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. *Exp Biol Med (Maywood).* 2007;232(9):1152–1159.

32. Wu Z, Zhang L, Li N, Sha L, Zhang K. An immunohistochemical study of thioredoxin domain-containing 5 expression in gastric adenocarcinoma. *Oncol Lett.* 2015;9(3):1154–1158.

33. Wang L, Song G, Chang X, et al. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway. *Oncogene.* 2015;34(36):4735–4745.

34. Jung EJ, Chung KH, Kim CW. Identification of simvastatin-activated targets associated with JNK activation in DU145 human prostate cancer cell death signaling. *BMB Rep.* 2017;50(9):466–471.

35. Charlton HK, Webster J, Kruger S, Simpson F, Richards AA, Whitehead JP. ERp46 binds to AdipoR1, but not AdipoR2, and modulates adiponectin signalling. *Biochem Biophys Res Commun.* 2010;392(2):234–239.

36. Turano C, Copparsi A, Altieri F, Ferraro A. Proteins of the PDI family: unpredicted non-ER locations and functions. *J Cell Physiol.* 2002;193(2):154–163.

37. Wu Y, Ahmad SS, Zhou J, Wang L, Cully MP, Essex DW. The disulfide isomerase ERP57 mediates platelet aggregation, hemostasis, and thrombosis. *Blood.* 2012;119(7):1737–1746.

38. Duivenvoorden WC, Paschos A, Hopmans SN, Austin RC, Pinthus JH. Endoplasmic reticulum protein ERp46 in renal cell carcinoma. *PLOS One.* 2014;9(3), e90389.

39. Camargo Lde L, Babelova A, Mieth A, et al. Endo-PDI is required for TNFalpha-induced angiogenesis. *Free Radical Biol Med.* 2013;65:1398–1407.

40. Zhang L, Hou Y, Li N, Wu K, Zhai J. The influence of TXNDC5 gene on gastric cancer cell. *J Cancer Res Clin Oncol.* 2010;136(10):1497–1505.

41. Lee SO, Jin UH, Kang JH, et al. The orphan nuclear receptor RXRA1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells. *Mol Cancer Res MCR.* 2014;12(4):527–538.

42. Wang L, Zheng Y, Xu H, Yan X, Chang X. Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis. *PLOS One.* 2013;8(1), e53301.

43. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. *J Biol Chem.* 2011;286(3):2047–2056.

44. Sauter W, Rosenberger A, Beckmann L, et al. Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. *Cancer Epidemiol Biomark Prev.* 2008;17(5):1127–1135.

45. Kudo Y, Iizuka S, Yoshida M, et al. Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis. *J Biol Chem.* 2012;287(46):38716–38728.

46. Chang X, Cui Y, Zong M, et al. Identification of proteins with increased expression in rheumatoid arthritis synovial tissues. *J Rheumatol.* 2009;36(5):872–880.

47. Chang X, Zhao Y, Yan X, Pan J, Fang K, Wang L. Investigating a pathogenic role for TXNDC5 in rheumatoid arthritis. *Arthritis Res Ther.* 2011;13(4):R124.

48. Jeong KH, Shin MK, Uhm YK, Kim HJ, Chung JH, Lee MH. Association of TXNDC5 gene polymorphisms and susceptibility to nonsegmental vitiligo in the Korean population. *Br J Dermatol.* 2010;162(4):759–764.
67. Salmans ML, Zhao F, Andersen B. The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker. *Breast Cancer Res BCR*. 2013; 15(2):204.

68. DiMaio MA, Kwok S, Montgomery KD, Lowe AW, Pai RK. Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping. *Hum Pathol*. 2012;43(11): 1799–1807.

69. Chung K, Nishiyama N, Wanibuchi H, et al. AGR2 as a potential biomarker of human lung adenocarcinoma. *Osaka City Med J*. 2012;58(1):13–24.

70. Dong A, Wodziak D, Lowe AW. Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface. *J Biol Chem*. 2015;290(13): 8016–8027.

71. Chevet E, Fessart D, Delom F, et al. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. *Oncogene*. 2013;32(20):2499–2509.

72. Ryu J, Park SG, Lee PY, et al. Dimerization of pro-oncogenic protein anterior gradient 2 is required for the interaction with BiP/GRP78. *Biochem Biophys Res Commun*. 2013;430(2): 610–615.